{"id":"W1594902063","doi":"10.1007/s00280-002-0566-8","title":"Phase I and pharmacokinetic study of anhydrovinblastine every 3 weeks in patients with refractory solid tumors","year":2003,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":14,"is_retracted":false,"has_abstract":false,"ca_institutions":"Discovery Air (Canada)","funders":"National Cancer Institute","keywords":"Pharmacokinetics; Refractory (planetary science); Medicine; Solid tumor; Maximum tolerated dose; Internal medicine; Oncology; Pharmacology; Cancer; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001294332,0.001369616,0.003482356,0.0007925368,0.0005520136,0.0009858913,0.001053274,0.001160924,0.002144763],"category_scores_gemma":[0.002432582,0.000745616,0.001155961,0.0008729845,0.001344981,0.0007873583,0.0003225315,0.004083031,0.0005269987],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001077413,"about_ca_system_score_gemma":0.001698469,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002643807,"about_ca_topic_score_gemma":0.002969121,"domain_scores_codex":[0.9992489,0.0004403522,0.00002303202,0.0001014314,0.00006457717,0.0001217218],"domain_scores_gemma":[0.9986314,0.0003865605,0.0002533671,0.0001773559,0.00006684816,0.0004844132],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7888151,0.06255195,0.003875235,0.0004704131,0.001157289,0.0002190173,0.0004966473,0.008622559,0.03136848,0.0007543119,0.00294492,0.09872409],"study_design_scores_gemma":[0.3922155,0.5885736,0.008344381,0.00002318984,0.0003455122,0.0001991896,0.00009138235,0.003491222,0.004395266,0.0002731881,0.002004522,0.00004311816],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.995716,0.001113992,0.0005954058,0.000328909,0.00008449047,0.0007570738,0.0004202732,0.00007380313,0.0009098872],"genre_scores_gemma":[0.9941939,0.001281137,0.001339343,0.0002619736,0.0001224235,0.0007898494,0.0005368766,0.00003510524,0.001439416],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003482356,"threshold_uncertainty_score":0.007817209,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1627209557731493,"score_gpt":0.5160638178940202,"score_spread":0.353342862120871,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}